Avesthagen teams with CosmosID for TB diagnosis method

Avesthagen Limited, an Indian systems biology biotechnology company, has signed a memorandum of understanding with CosmosID, a U.S. based company, to collaborate on better diagnosis and management of tuberculosis treatment.

Avesthagen and CosmosID will work together to identify specific TB strains and support proper patient treatment. The companies anticipate the creation of a new method to develop diagnostic kits for the rapid screening of patient samples.

"Tuberculosis is a serious infectious disease and the efficacy of its treatment lies in accurate and rapid identification of the TB strains," Villoo Morawala-Patell, the founder and chief managing director of Avesthagen, said. "Avesthagen has been working on TB for some time and has developed a genomic data pool. In CosmosID we have found a leader and strong partner, developing rapid pathogen identification methods, MetaSeq Genomics, to facilitate more precise diagnostic screening of infectious disease in a single, rapid, and accurate test. The collaboration will help in improving the healthcare in developing and lesser developed countries where it is needed the most."

Tuberculosis is a tropical disease caused by Mycobacterium tuberculosis that can mutate into various strains that can be infectious or non-infectious. TB patients are usually treated with antibiotics without analysis of the particular strain. By developing testing kits to identify TB strains, the companies may be able to determine early on if a certain strain has resistance to a certain antibiotic.

"We are proud to be associated with Avesthagen on this important project," Rita Colwell, the founder and chairman of CosmosID, said. "Our collaboration will provide significant benefits for TB patients worldwide and demonstrates a new paradigm for medical diagnostic screening of infectious disease."